This study aims to address the following objectives:
1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in
patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms
of improving the time to resolution of disease.
2. To determine the efficacy of IC14 in reducing the severity of respiratory disease in
patients hospitalized with respiratory disease due to SARS-CoV-2.
3. To determine the safety of IC14 in patients hospitalized with respiratory disease due to
SARS-CoV-2.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Implicit Bioscience PPD University of Washington Vanderbilt University Medical Center